ORA™ reveals in world premiere its new range of innovative NEPTIS® synthesizers for PET radiopharmaceuticals incorporating WNE® system during SNMI-2013

Philippeville, Belgium, June 8th June 2013 / Optimized Radiochemical Applications (ORA™) today announced it is presenting as a world premiere its new range of NEPTIS® synthesizers for the production of PET radiopharmaceuticals incorporating the WNE® system.

WNE® system is a unique patented technology allowing the design of 3-position pneumatic actuator, offering more flexibility for complex fluid pathways and radiation resistance for PET synthesizers that are operating in radioactive environment.

This new range consists of several models offering distinctive technical features but all of them incorporating a common technology (WNE® system), the latest generation of Rockwell PLC and a new version of the control software (v2.0).

  • NEPTIS® perform is an integrated synthesiser with HPLC and SPE reform for advanced and complex tracers, that fits in a standard mini-cell.
  • NEPTIS® mosaic-RS is a compact synthesizer compatible with several commercially available kits for generic tracers. Two synthesizers can fit in a standard mini-cell, so that two synthesis can be performed at the same time. It reduces significatively the needed hotcell investment.
  • NEPTIS® mosaic-LC is an ultra-compact synthesizer for optimizing “to the max” running production costs. Up to four synthesizers can fit in a standard mini-cell, so that four synthesis can be performed at the same time. It reduces considerably the needed hotcell investment.

ORA™ is exhibiting all these new models at booth number #1500 at the Society for Nuclear Medicine (SNM) Annual Meeting 2013 from 8-12 June in Vancouver, Canada.


NEPTIS® synthesizers, dedicated for the production of PET radiopharmaceuticals, aimed since their inception to address the various challenges, different by nature, of personalized medicine, a young but rapidly advancing field of healthcare: restoring freedom for researchers with an open and flexible platform, providing developers with a robust tool from clinical trials to commercial production, and offering producers a guarantee of reliable and repetitive performance. Additional information about NEPTIS® is available at www.neptis-vsa.com.

About Optimized Radiochemical Applications (ORA™)

ORA, an innovation-driven Belgian company based founded in 2006, is developing an extensive range of PET synthesizers for existing and new radiopharmaceuticals and collaborates with major research institutions and pharmaceutical companies worldwide. Additional information about ORA is available at www.oradiochem.eu.

For immediate release

Contact: Vincent Tadino
Phone: (0032) 71 61 40 53
Email: info@oradiochem.eu


©ORA Belgium, 2013. All rights reserved. PR13001
NEPTIS® is a trademark of ORA™

Print Friendly, PDF & Email